ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1579

Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Abstract Number: 1580

Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis
Abstract Number: 1581

The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
Abstract Number: 1582

Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Abstract Number: 1583

Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
Abstract Number: 1584

Evaluation of Adverse Childhood Experiences in Systemic Sclerosis: Prevalence and Patient Characteristics
Abstract Number: 1586

Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study
Abstract Number: 1587

Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains
Abstract Number: 1588

Prevalence Of Oral Manifestations And Their Association With Clinical And Serological Profile In Systemic Sclerosis Patients- An Indian Study
Abstract Number: 1589

Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation
Abstract Number: 1590

Association of levels of soluble CD13 with clinical features and fibrosis in systemic sclerosis patients
Abstract Number: 1591

Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
Abstract Number: 1592

Mepolizumab to Benralizumab Switch in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Abstract Number: 1593

Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients
Abstract Number: 1594

Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].